- Home
- VMD vs ALT Comparison
VMD vs ALT Comparison
Compare VMD & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VMD | ALT |
|---|---|---|
| Founded | 2006 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 465.4M | 421.5M |
| IPO Year | 2018 | 2005 |
Fundamental Metrics
Financial Performance| Metric | VMD | ALT |
|---|---|---|
| Price | $11.75 | $2.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 335.1K | ★ 3.9M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.14 | 25.37 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $270,280,000.00 | $41,000.00 |
| Revenue This Year | $17.88 | N/A |
| Revenue Next Year | $14.98 | N/A |
| P/E Ratio | $194.50 | ★ N/A |
| Revenue Growth | 20.52 | ★ 105.00 |
| 52 Week Low | $5.93 | $2.56 |
| 52 Week High | $12.61 | $6.44 |
Technical Indicators
Market Signals| Indicator | VMD | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 41.51 |
| Support Level | $11.71 | $2.72 |
| Resistance Level | $12.61 | $3.09 |
| Average True Range (ATR) | 0.35 | 0.13 |
| MACD | -0.11 | -0.03 |
| Stochastic Oscillator | 28.18 | 6.27 |
Price Performance
Historical ComparisonAbout VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.